Robert Sutherland Smith started his City career the year before I was born. He is, I think, 157 years old. He and I have worked together for almost eight years at t1ps.com . He is my friend and he is a very funny and intelligent chap. He is now branching out to celebrate his 158th by doing some freelance writing over at TradingResearchPoint on FTSE 350 Income stocks. He is a great one for focussing on yield. RSS today looks at AstraZeneca.
Whatever else, the annual results from that curiosity of the pharmaceutical sector, the Anglo-Swedish company AstraZeneca (AZN) tells us that the company’s management is thinking about dividend policy but presumably not telling us all they think. So here are my Hercule Poirot like surmises. Smoothing the waxed moustache, taking the cane from the umbrella stand and giving oneself an admiring glance in the art deco hall mirror, I mince forward, stimulating my little grey cells – such as they are – as I go.Read the full article on TradingResearchPoint | Comments comments powered by Disqus